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Objectives. IL-33, a newly found cytokine which is involved in joint inflammation, could be blocked by a decoy receptor—sST2.The
expression and correlation of IL-33 and sST2 in rheumatoid arthritis (RA) are of great interest. Methods. Synovial fluid (SF) was
obtained from 120 RA and 30 osteoarthritis (OA) patients, and paired sera were collected from 54 of these RA patients. The levels
of IL-33 and sST2 were measured by ELISA. Results. SF IL-33 was significantly higher in RA than in OA, which was correlated with
disease activity score 28, erythrocyte sedimentation rate, rheumatoid factor (RF)-IgM, RF-IgG, glucose phosphate isomerase (GPI),
and immunoglobulin. Serum IL-33 was correlated positively with SF IL-33 in RA. Furthermore, it was correlated with RF-IgM and
GPI. sST2 was partly detectable in RA (13 out of 54, 24.1%), while not in OA. Serum sST2 in RA had no significant correlation with
serum IL-33 or SF IL-33. However, SFs from both RA and OA patients did not express sST2. Conclusions. This study supported
that IL-33 played an important role in the local pathogenesis of RA. Considering the tight correlation between IL-33 and clinical
features, it may become a new target of local treatment.
1. Introduction
Rheumatoid arthritis (RA) is a chronic, inflammatory auto-
immune disease characterized by the joints erosion and dam-
age. Current research suggests that cytokines play important
roles in the immunopathogenesis of RA.
IL-33, a member of the IL-1 cytokine family, is involved in
the inflammation of RA via the IL-1 receptor-related protein
ST2, and the recruitment of IRAK, IRAK4, MyD88, and
TRAF6 to ST2, ultimately leading to the activation of NF-𝜅B
and MAP kinases [1]. The soluble form of ST2-sST2, is con-
sidered as a decoy receptor to block the effect of IL-33. IL-33
exacerbates the disease severity of collagen-induced arthritis
(CIA) which is an animal model of RA disease [2]. Inhibi-
tion of IL-33 signaling pathway through blocking anti-ST2
antibody attenuated the severity of CIA [3]. It was reported
that sST2 administration could also attenuate the severity of
CIA [4]. Some recent studies have further shown that IL-33
is expressed by the synovial fibroblasts from RA patients
[2, 3, 5] and the serum level of IL-33 is abnormally elevated in
these patients [6–9]. However, the levels of IL-33 and sST2 in
the synovial fluid (SF) and whether they are associated with
disease activity are less known.
In this study, we compared the expression of IL-33 and
sST2 in SF and paired serum samples of patients with RA to
that with osteoarthritis (OA) and analyzed their association
with clinical characteristics of RA disease.
2. Materials and Methods
2.1. Patients and Samples. SF samples were obtained from 120
patients with RA and 30 patients with OA in an outpatient
clinic of the Department of Rheumatology and Immunology,
Peking University People’s Hospital, from December 2009 to
December 2010. Paired sera of 54 RA patients and 12 OA
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Table 1: Characteristics of enrolled patients with RA and OA.
Samples Diseases n Gender Age Disease duration
M/F P Range (year, mean ± SD) P Range (year, mean ± SD) P
SF RA 120 23/97 0.457 12–81 (53.8 ± 16.1) 0.111 0.3–30 (9.4 ± 8.4) 0.847
OA 30 4/26 40–77 (57.8 ± 11.3) 0.1–30 (11.1 ± 8.4)
Serum RA 54 6/48 0.347 23–81 (55.6 ± 13.4) 0.423 0.3–30 (8.2 ± 7.4) 0.524
OA 12 3/9 53–72 (61.4 ± 10.4) 0.1–30 (6.6 ± 8.2)
RA: rheumatoid arthritis; OA: osteoarthritis; SF: synovial fluid.
patients were also collected. All patients were grouped
according to the revised criteria of the American College of
Rheumatology for RA [10] or for OA [11]. The study was
approved by the ethics committee of People’s Hospital, Peking
University, according to the Declaration of Helsinki. All
patients had been informed and signed the consent for
participation in the study.Thedetails of the patients including
gender, age, and disease durationwere summarized in Table 1.
2.2. Measurement of IL-33 and sST2. Serum and SF IL-33
concentrations were determined with a commercial ELISA
kit (DY3625, R&D Systems, Minneapolis, MN, USA). Serum
samples were diluted 1 : 2 in sample dilution buffer. Soluble
ST2was assessed by ELISA using a commercial detection sys-
tem (DST200, R&D Systems, Minneapolis, MN, USA). The
experiments were performed according to themanufacturer’s
instructions.
2.3. Clinical Data and Inflammation Marker Analysis. Clini-
cal data were recorded at the time of sample collection as the
following index: age, sex, disease duration, number of swollen
joints, and number of tender joints. Erythrocyte sedimen-
tation rate (ESR) was evaluated by the Westergren method.
Serum levels of immunoglobulins (IgG, IgM, and IgA,), com-
plements (C3, C4), C-reactive protein (CRP), and rheuma-
toid factor (RF)-IgM were examined by immunonephelom-
etry method. Antikeratin antibodies (AKA) and antiperin-
uclear factor (APF) were tested by indirect immunofluores-
cence assay. Anti-citrullinated peptide (anti-CCP) antibod-
ies, glucose phosphate isomerase (GPI), and RF-IgG were
tested by ELISA. The 28-joint count Disease Activity Score
(DAS28) was evaluated as described [12].
2.4. Statistical Analysis. Data analyses were performed using
SPSS 13.0 for Windows. Results are presented as the mean ±
SD and percentage. Quantitative data were compared by the
Mann-Whitney𝑈 test. Qualitative data were compared by the
Pearson’s chi-square test. Paired samples were analyzed using
theWilcoxonmatched pairs test. A difference between groups
was considered significant if 𝑃 < 0.05. Spearman’s rank cor-
relation test was used to assess relationships between two
variables. Correlation was considered significant if 𝑃 < 0.05.
3. Results
3.1. IL-33 in Matched Serum-SF Samples of RA. IL-33 level
was measured in the matched serum-SF samples of 54 RA
patients. The level of IL-33 in SF (median 15.24 pg/mL) was
lower than that in sera (median 31.64 pg/mL, Figure 1(a)).
Spearman’s correlation test was used to analyze the correla-
tion of IL-33 levels in SF and in serum of RA.There is a signif-
icant correlation between two groups (𝑟 = 0.578, 𝑃 < 0.001,
Figure 1(b)).
3.2. IL-33 Levels in SF of RA and OA. The minimal concen-
tration of standard (23.35 pg/mL) was assumed as the detec-
tion limit. SF IL-33 was detectable in 43 of the 120 patients
with RA (35.8%), while none of the 30 OA patients had
detectable level of IL-33 in their SF. SF IL-33 level in RA
patients was significantly higher than that of OA patients
(35.56 ± 62.56 pg/mL versus 3.66 ± 5.63 pg/mL, 𝑃 < 0.001,
Figure 2).
A correlation was analyzed between the clinical features
and IL-33 levels in SF and serum of patients with RA. Com-
paring to the serum IL-33, SF IL-33 level in RA hadmore cor-
relations with clinical features including disease activity fea-
tures (ESR, DAS28 score) and autoantibodies (RF-IgM, RF-
IgG, GPI, IgA, IgG, and IgM). The data was shown in Table 2
and Figure 3.
3.3. SF IL-33 Was Correlated with Disease Activity in RA.
These 120 patients with RA were classified into 3 groups
according to the DAS28-ESR: the high activity group (47
patients) was defined as DAS28-ESR > 5.1; the moderate
activity group (56 patients) was defined as 5.1≥DAS28-ESR>
3.2; the low activity group (17 patients) was defined asDAS28-
ESR ≤ 3.2 [12]. SF IL-33 levels were significantly higher in the
high and moderate activity groups than in the low activity
group (𝑃 = 0.0319 and 0.0006, resp.; Figure 4).
Correspondingly, RA patients were divided into SF-IL-
33-positive and SF-IL-33-negative groups according to the
minimal detection limit of IL-33 (23.35 pg/mL), and the char-
acteristics of these groups are shown in Table 3. It showed
that the SF-IL-33-positive group had higher DAS28, ESR, and
CRP than the SF-IL-33-negative group.
3.4. SF-IL-33 Was Correlated with Autoantibody Production
in RA. It was shown in Table 2 that the level of SF-IL-33
was correlated with the levels of several auto-antibodies in
serum including RF-IgM, RF-IgG, GPI, IgG, IgA, and IgM in
patients with RA.
We also found in Table 3 that the SF-IL-33-positive group
had higher levels of RF-IgM, IgG, IgA, and IgM than the SF-
IL-33-negative group.The positive frequency of GPI was also
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Figure 1: IL-33 levels in serum and SF samples in 54 RA patients were measured simultaneously. The levels in SF (median 15.24 pg/mL) were
lower than those in sera (median 31.64 pg/mL (a)). A significant correlation between two groups was estimated by Spearman’s correlation test
(𝑟 = 0.578, 𝑃 < 0.001 (b)).
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Figure 2: IL-33 levels in SF of RA andOA. SF IL-33was detectable in
43 of the 120 patients with RA (35.8%), whereas it was nondetectable
in patients with OA. The concentration in SF from RA was
significantly higher than that from OA (𝑃 < 0.001).
higher in the SF-IL-33-positive group than in the SF-IL-33-
negative group.
Similarly, SF IL-33 concentration in GPI-positive patients
(53.96 ± 71.43 pg/mL) was higher than that in GPI-nega-
tive patients (24.85 ± 66.81 pg/mL, 𝑃 = 0.002). A similar
trend was identified in RF-IgM-positive patients (42.58 ±
59.85 pg/mL versus 22.98 ± 65.96 pg/mL, 𝑃 = 0.001).
3.5. sST2 inMatched Samples of RAandOA. Soluble ST2 con-
centration in matched serum-SF samples of 54 RA patients
and 12 OA patients was also measured by ELISA. The ref-
erence serum interval of kit (6.74–20.4 ng/mL) was used as
Table 2: Correlation analysis between SF-serum IL-33 (pg/mL) and
clinical and laboratory variables.
Measurements SF IL-33 (𝑛 = 120) Serum IL-33 (𝑛 = 54)
r P r P
Age (yrs) −0.106 0.257 −0.014 0.921
Tender joint count,
0–46 joints 0.095 0.347 0.327 0.020
∗
Swollen joint count,
0–48 joints 0.192 0.056 0.134 0.354
DAS28-ESR 0.209 0.047∗ 0.253 0.102
ESR (mm/h) 0.256 0.008∗ 0.213 0.150
CRP (mg/L) 0.166 0.073 0.219 0.116
C3 (g/L) 0.113 0.260 0.267 0.061
C4 (g/L) 0.039 0.698 0.180 0.211
IgA (g/L) 0.246 0.012∗ 0.107 0.457
IgG (g/L) 0.309 0.001∗ 0.136 0.343
IgM (g/L) 0.301 0.002∗ 0.220 0.121
RF-IgM (U/mL) 0.327 <0.001∗ 0.342 0.011∗
RF-IgG (IU/mL) 0.214 0.037∗ 0.183 0.208
GPI (mg/L) 0.364 0.001∗ 0.505 0.000∗
Anti-CCP (RU/mL) 0.104 0.284 0.052 0.716
∗P < 0.05. Spearman’s correlation test was used.
the boundary. It showed that serum sST2 was elevated in
13 of the 54 patients with RA (24.1%) while none of the
OA patients had a detectable level of sST2. No significant
difference of SF sST2 concentrations was observed between
RA (3.14±1.94 ng/mL) and OA (3.20±1.71 ng/mL) patients.
Furthermore, there was no correlation between serum sST2
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Figure 3:The significant correlations between SF IL-33 and clinical features including disease activity features (ESR, DAS28 Score) and auto-
antibodies (RF-IgM, RF-IgG, GPI, IgA, IgG, and IgM). ESR: erythrocyte sedimentation rate; RF: rheumatoid factor; GPI: glucose phosphate
isomerase.
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Table 3: The comparison of clinical features between SF-IL-33-positive and SF-IL-33-negative groups.
Measurements SF-IL-33-positive (𝑛 = 43) SF-IL-33-negative (𝑛 = 77) Z (𝑥2) P
Age (yrs) 49.9 ± 18.5 56.0 ± 14.2 −1.490 0.136
Gender (M/F) 11/32 12/65 1.220 0.325
Disease duration (yrs) 10.2 ± 8.9 9.0 ± 8.0 −0.515 0.607
Tender joint count 8.1 ± 8.3 6.9 ± 7.8 −0.847 0.397
Swollen joint count 8.1 ± 8.0 5.4 ± 7.0 −1.789 0.074
DAS28 5.3 ± 1.2 4.7 ± 1.3 −2.103 0.035∗
ESR (mm/h) 66.7 ± 33.0 48.7 ± 33.2 −2.976 0.003∗
CRP (mg/L) 49.3 ± 39.4 34.9 ± 32.3 −2.055 0.040∗
RF-IgM (U/mL) 440.7 ± 646.0 186.8 ± 378.6 −3.564 <0.001∗
RF-IgG-positive 46.5% (20) 27.3% (21) 3.136 0.110
GPI-positive 67.4% (29) 41.6% (32) 5.332 0.026∗
IgA (g/L) 3.9 ± 1.6 3.1 ± 1.4 −2.258 0.024∗
IgG (g/L) 17.1 ± 5.4 14.0 ± 4.7 −2.888 0.004∗
IgM (g/L) 1.6 ± 0.8 1.2 ± 0.7 −3.064 0.002∗
C3 (g/L) 1.2 ± 0.4 1.1 ± 0.3 −1.002 0.317
C4 (g/L) 0.2 ± 0.1 0.2 ± 0.1 −0.077 0.939
Anti-CCP (RU/mL) 107.9 ± 80.3 97.0 ± 81.6 −0.937 0.349
AKA-positive 21 (48.8%) 42 (54.5%) 0.269 0.383
APF-positive 25 (58.1%) 50 (64.9%) 0.367 0.651
∗P < 0.05.
SF IL-33-positive: SF IL-33 ≥ 23.35 pg/mL; SF IL-33-negative: SF IL-33 < 23.35 pg/mL.
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Figure 4: Interleukin 33 (IL-33) levels in synovial fluid (SF) from
RA patients. RA patients were categorized into 3 groups according
to the Disease Activity Score based on ESR. Low: low activity group;
Mod: moderate activity group; High: high activity group. Symbols
represent individual samples. Horizontal bars represent median IL-
33 levels.
and serum IL-33 level or SF IL-33 level, showing that the rela-
tionship between sST2 and IL-33 in RA needs more effort to
be understood.
4. Discussion
According to our knowledge, this is the largest study of IL-33
and sST2 in SF and matched serum of RA and OA patients.
Comparing to the former studies [6–9], it could provide the
more believable results about the expression of IL-33 in RA.
Based on the present study, we found that there was an
obvious difference of IL-33 levels between SF and matched
serum. We also demonstrated that SF-IL-33 in RA patients
had higher levels than OA patients, whether with positive
rate or mean expression. Additionally, our study showed that
there was a positive correlation between SF-IL-33 and disease
activity or RA-associated auto-antibodies, which supported
the hypothesis that IL-33 plays an important role in the path-
ogenesis of RA.
In our study, SF IL-33 levels were significantly higher in
the high andmoderate activity groups than in the low activity
group. On the other hand, the SF-IL-33-positive group had
higher DAS28, ESR, and CRP than the SF-IL-33-negative
group. It suggested that SF IL-33 was closely associated with
systemic inflammation.
Furthermore, the SF-IL-33-positive group had higher lev-
els of RF-IgM, IgG, and IgA and positive frequency of GPI
than the SF-IL-33-negative group. The result of our former
study [7], that serum IL-33 is associated with antibody pro-
duction, was also proved with SF-IL-33. All these antibodies
are important features for diagnosis and prognosis [13–
15], so we considered that IL-33 may be a risk factor for
poor prognosis in RA. Further study is deserved about the
mechanism of IL-33 in inducing antibody production.
As a specific ligand of IL-33, sST2 can serve as an anti-
inflammatory mediator through binding with IL-33, sequen-
tially decrease the interaction of IL-33 and ST2L [16]. There-
fore, we need to know the expression of sST2 in RA SF and
serum to further understand its function in the pathogenesis.
In our study, the positive frequency of serum sST2 in RA
patients was higher than that in OA patients, but there was no
significant difference.The concentrations of SF sST2 also had
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no difference between RA and OA. Since the expression of
sST2 could be induced in various mesenchymal and hemato-
poietic cells by a lot of stimuli [17–20], therefore, it is possible
that the inflammatory milieu is responsible for the level of
sST2 in OA. We tried to find out the relationship between
serum sST2 and serum IL-33 or the other clinical features in
RA, but no correlation was observed. The similar result was
also shown in a previous study [9], which was held by a rela-
tive low number of samples.
In conclusion, SF IL-33 levels that increased in RA
patients could be treated as a sensitivemarker of disease activ-
ity andwere associatedwith the production of antibodies.The
correlated expression of IL-33 between SF and serum suggests
that IL-33 plays an important role in the local pathogenesis of
RA. It may become a new target of local treatment. The role
of sST2 and the therapeutic significance of IL-33/sST2 system
in RA need further research.
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